Evidence map›Paper›PMID 37644893›Full record

ArticleAddiction biology2023

Chronic administration of a norepinephrine antagonist prevents and partially reverses escalation of cocaine self-administration.

Hassiba Beldjoud, Alicia Avelar, Giordano de Guglielmo, Marsida Kallupi, Sharona Sedighim, Nathan Velarde, Brent Boomhower, Nathan Rizo, Lieselot L G Carrette, Olivier George

Open access · hybridAbstract read
In one paragraph

Article in Addiction biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Hassiba BeldjoudDepartment of Psychiatry, UC San Diego School of Medicine, La Jolla, California, USA.
Alicia AvelarDepartment of Psychiatry, UC San Diego School of Medicine, La Jolla, California, USA.ORCID 0000-0003-1414-5748
Giordano de GuglielmoDepartment of Psychiatry, UC San Diego School of Medicine, La Jolla, California, USA.
Marsida KallupiDepartment of Psychiatry, UC San Diego School of Medicine, La Jolla, California, USA.
Sharona SedighimDepartment of Psychiatry, UC San Diego School of Medicine, La Jolla, California, USA.
Nathan VelardeDepartment of Psychiatry, UC San Diego School of Medicine, La Jolla, California, USA.
Brent BoomhowerDepartment of Psychiatry, UC San Diego School of Medicine, La Jolla, California, USA.
Nathan RizoDepartment of Psychiatry, UC San Diego School of Medicine, La Jolla, California, USA.
Lieselot L G CarretteDepartment of Psychiatry, UC San Diego School of Medicine, La Jolla, California, USA.
Olivier GeorgeDepartment of Psychiatry, UC San Diego School of Medicine, La Jolla, California, USA.
University of California San Diego · USScripps Research Institute · US

Funding

Neurpsychopharmacology-Multidisciplinary TrainingT32AA007456 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI MARISA ROBERTO · 1985 to 2026
$13.4M
Identification of Genetic Variants that Contribute to Compulsive Cocaine Intakein RatsU01DA043799 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Olivier George, Abraham A Palmer · 2017 to 2026
$7.9M
NIAAA NIH HHS T32 AA007456NIDA NIH HHS U01 DA043799
6 · The paper itself

Abstract

Anxiety is a critical component of the development and maintenance of drug addiction; however, anti-anxiety medications such as benzodiazepines and beta-blockers (β-adrenergic receptor antagonists) are not used for the treatment of substance use disorder, except for the management of acute withdrawal syndrome. Preclinical studies have shown that beta-blockers may reduce stress-induced relapse; however, the effect of beta blockers on the escalation and maintenance of drug intake has not been tested. To address this issue, we chronically administered the β-adrenergic receptor antagonist propranolol during the escalation or maintenance of cocaine intake in a model of extended access (6 h) to cocaine self-administration (0.5 mg/kg). The behavioural specificity of propranolol was tested using a non-drug reward (saccharin). Daily administration of propranolol (15 mg/kg) prevented the development of escalation of cocaine self-administration and partially reversed self-administration after the establishment of escalation of intake. Moreover, propranolol dose-dependently decreased the motivation for cocaine tested under a progressive ratio schedule of reinforcement during the development of escalation and after maintenance. Finally, propranolol administration had no effect on the escalation and maintenance of saccharin self-administration. These results demonstrate that chronic treatment with propranolol provides therapeutic efficacy in reducing cocaine self-administration during the development and after the establishment of escalation of cocaine self-administration in an animal model relevant to cocaine use disorder. These results suggest that beta blockers should be further investigated as a target for medication development for the treatment of cocaine use disorder.

Indexed as

CocainePropranololAnimalsNorepinephrineSaccharinSelf AdministrationCocaineNorepinephrinePropranololSaccharinbeta-blockermotivationnorepinephrinestresssubstance-use disorderstherapeutics

Identifiers

PMID37644893
PMCPMC10614571
OpenAlexW4386002123

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.